L2i / 23A19: Describe factors that prolong the action of neuromuscular blocking agents (60% marks).  Outline the pharmacokinetics and pharmacodynamics of vecuronium (40% marks)

L2i / 22A13: Compare and contrast the pharmacology of Suxamethonium and Rocuronium

L1iii / 22A12: Describe the process of excitation-contraction coupling and relaxation in smooth muscle

L2i / 21A06: Describe the pharmacology of vecuronium, including factors that prolong its action of neuromuscular blockade

L2i / 20B10: Describe the pharmacology of suxamethonium

L3i: Describe the monitoring of neuromuscular blockers

L2i / 18A10 : Outline the advantages and diasdvantages of SUX

L2i / 14B07 : Outline mechanisms that potentiate the action of NDMR and give examples 15%

L2i / 18A14 / 15A21 : Classify Anticholinesterase drugs according to chemical interaction with an example of each (30). Outline the PD effects of anticholinesterase drugs and their clinical indications (70)

L2i: Cholinesterases

L2i: Pharmacology of NDMR

L2i / 16A12 / 14A09: Factors which influence speed of neuromuscular blockade

L2i / 18B13: Compare and contrast rocuronium and cisatracurium

L1i / 15B11: Compare and contrast the anatomy and physiology of skeletal muscle and smooth muscle

L1iii / 14A08: Describe the physiology of skeletal muscle contraction

L1iv / 19B03: Describe the relationship between muscle length and tension. Outline the significance of this relation ship in cardiac muscle

L1i: Describe the anatomy and physiology of skeletal, smooth and cardiac muscle

L1ii / 19A17: Explain the physiology of neuromuscular transmission